Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 4Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Breast Neoplasms 3Thymoma 1Thymic epithelial tumor 1Squamous NSCLC 1Mediastinal Neoplasms 1Lung Neoplasms 1Gallbladder Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Advanced Gastric or Gastroesophageal Junction Adenocarcinoma 1

Interventions

Cisplatin 8Radiotherapy 6Fluorouracil 4Paclitaxel 3tislelizumab 2nimotuzumab 2Neoadjuvant Therapy 2Esophagectomy 2Drug Therapy 2Capecitabine 2spartalizumab 1pembrolizumab 1anlotinib 1TP protocol 1Surgical Procedures, Operative 1Radiation 1Oxaliplatin 1Nivolumab 1Leucovorin 1Immunotherapy 1Docetaxel 1Clinical Trials, Phase II as Topic 1Chemoradiotherapy 1Cetuximab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Esophageal Squamous Cell Carcinoma × 130-nm albumin-bound paclitaxel × Clear all
NCT06861777 2025-03-11

Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2/3 Not yet recruiting
474 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡